Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.
The number of adults diagnosed with diabetes has more than quadrupled since 1990 and now stands above 800 million, according ...
The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...
The weight loss drugs Ozempic and Wegovy may be beneficial for people struggling with alcohol addiction, a study published ...
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...
Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...
Jim Gaffigan has always used his weight and love for eating as a punchline in his comedy, even going so far to title his 2013 ...
Healthy diet and regular exercise are key to treating obesity. But the stress of everyday racism and sexism hinder Black ...
Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...
Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback